Literature DB >> 22262287

Sentinel lymph node biopsy in patients with conjunctival and eyelid cancers: experience in 17 patients.

Toufic J Maalouf1, Gilles Dolivet, Karine S Angioi, Agnes Leroux, Pascal Genin, Jean-Luc George.   

Abstract

PURPOSE: To assess lymph node invasion through the use of sentinel lymph node biopsy (SLNB) in conjunctival and eyelid tumor patients and ascertain the impact of this technique in therapeutic management recommended by the multidisciplinary consensus committee.
METHODS: A single center prospective nonrandomized clinical study was conducted between January 2008 and January 2010. Seventeen patients were included: 4 (2 conjunctiva and 2 eyelid) melanomas, 4 eyelid Merkel cell tumors, 8 (2 conjunctiva, 2 eyelid, 2 eyelid and conjunctiva, 2 cornea and conjunctiva) squamous cell tumors, and 1 eyelid meibomian carcinoma. Preoperative lymphoscintigraphy was done the day before surgery to label lymph node(s). The surgical biopsy was then performed along with an extemporaneous pathological examination followed by secondary complete lymph node dissection only in instances of positive histology.
RESULTS: In all cases, one or more sentinel lymph nodes were identified (3-13). Two biopsies (1 Merkel cell carcinoma and 1 squamous cell carcinoma) revealed neoplastic invasion and led to complete cervical node dissection. Adjunct regional treatment was indicated for 1 melanoma, for 4 Merkel cell tumors, and for 2 squamous cell carcinomas. One false negative result was noted in the group of squamous cell carcinomas after 6 months, and it was treated. No relapse or death was observed for the other 16 patients. The mean overall follow-up was 18.2 months.
CONCLUSION: As in previous studies, we found that SLNB for eyelid and conjunctival tumors is safe and effective in identifying microscopically positive SLNs. This procedure may also revive interest in the study of cervicofacial lymphatic drainage. Our current investigation is to be expanded and extended to other medical teams.

Entities:  

Mesh:

Year:  2012        PMID: 22262287     DOI: 10.1097/IOP.0b013e31822fb44b

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   1.746


  7 in total

1.  Prognostic value of clinical and pathologic T stages defined by the American Joint Committee on Cancer for eyelid sebaceous carcinoma in Korea.

Authors:  Youn Joo Choi; Hyun Chul Jin; Min Joung Lee; Namju Kim; Ho-Kyung Choung; Sang In Khwarg
Journal:  Jpn J Ophthalmol       Date:  2014-04-25       Impact factor: 2.447

Review 2.  Sentinel lymph node biopsy for eyelid and conjunctival tumors: what is the evidence?

Authors:  Pia R Mendoza; Hans E Grossniklaus
Journal:  Int Ophthalmol Clin       Date:  2015

3.  Management of Conjunctival Melanoma: Critical Assessment of Sentinel Lymph Node Biopsy.

Authors:  Hassan A Aziz; Brian R Gastman; Arun D Singh
Journal:  Ocul Oncol Pathol       Date:  2015-05-06

4.  Sentinel lymph node biopsy in periocular merkel cell carcinoma: a case report.

Authors:  Dan C Filitis; Gyorgy Paragh; Faramarz H Samie; Nathalie C Zeitouni
Journal:  BMC Res Notes       Date:  2017-09-20

Review 5.  A systematic review of patients with Merkel cell carcinoma of the head and neck and a negative sentinel lymph node biopsy.

Authors:  Nigel G Maher; Dédée F Murrell
Journal:  Int J Womens Dermatol       Date:  2015-02-28

Review 6.  Sentinel lymph node biopsy in the management of conjunctival melanoma: current insights.

Authors:  Joel M Mor; Alexander C Rokohl; Konrad R Koch; Ludwig M Heindl
Journal:  Clin Ophthalmol       Date:  2019-07-23

7.  Evaluation of the radiotherapy management of ocular surface squamous neoplasia in a high HIV prevalence setting- a retrospective review.

Authors:  Ntokozo Ndlovu; Sandra Ndarukwa; Webster Kadzatsa; Simbarashe Rusakaniko
Journal:  Infect Agent Cancer       Date:  2016-04-20       Impact factor: 2.965

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.